

**PHARMACOVIGILANCE AMONG PATIENTS WITH MULTI DRUG RESISTANCE  
TUBERCULOSIS (MDR-TB) AND EXTENSIVELY DRUG-RESISTANT  
TUBERCULOSIS (XDR-TB) TREATMENT – A PROSPECTIVE STUDY**

P Narayana Swamy<sup>\*1</sup>, Dr. V Santhosh Kumar<sup>2</sup>.

<sup>1</sup> School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Pallavaram Chennai - 600 117

<sup>2</sup> Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Pallavaram Chennai - 600 117

**ABSTRACT**

**Background:** ADRs are frequent in patients of MDR-TB on DOTs-Plus drug regimen. Current study was carried out in tertiary care hospital. Recognition of types and frequency of adverse drug reactions in Intensive and continuation phase of MDR- TB Patients.

**Methods:** It was a prospective observational study conducted in Damien Foundation Urban Leprosy & TB Centre, Nellore. All the MDR-TB and XDR-TB patients admitted at the directly observed treatment, short course plus (DOTS plus) Center were enrolled and were monitored for ADRs. The causality and severity of the reactions were determined using Naranjo algorithm and Hartwig questionnaire, respectively.

**Results:** A total of 150 tuberculosis patients of MDR-TB on DOTS therapy were enrolled for the study. Out of 150 patients, 5 were dropouts, 3 died, 8 defaulted so 142 patients assessed for ADRs, 88 patients developed 61 (56.48%) adverse drug reactions. The higher numbers of ADRs were observed in age group 31- 40yrs followed by 21-30yrs which were more common in men. Majority of adverse drug reactions were Gastrointestinal (GI) problems 24 (27.27%), followed by Ototoxicity 7 (7.95%) and Psychiatric Manifestations 3 (3.40%) and skin problems 5 (5.68%). On evaluation of the causality of ADRs, majority were found to be Possible (57.95%). The severity assessment showed that most of the patients ADRs were of moderate level (42.04%).

**Conclusions:** ADRs are major factor limiting completion of drug therapy under RNTCP and occurrence of drug resistance which requires attention of all health care professionals.

**Key words:** ADRs; Causality and severity, DOTS therapy; Drug resistance; MDR-TB

**INTRODUCTION:**

Tuberculosis (TB) was declared a global emergency by the World Health Organization (WHO) in 1994. The incidence of TB is diminishing globally by approximately 2% each year and TB-related mortality decreased by 45% between 1995 and 2012; nonetheless, in 2012, 8.6 million people developed the disease and 1.3 million died from it. Despite the fall in incidence and mortality, multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB are presenting enormous new challenges in the management and control of this disease (Box 1). The WHO estimated there were 450,000 incident cases of drug-resistant TB and 170,000 drug-resistant TB-related deaths in 2012 worldwide.<sup>1</sup> Unfortunately, less than 25% of the estimated cases of MDR-TB are detected due to insufficient drug resistance testing. Currently, among notified cases globally, 3.6% of new cases and 20% of retreatment cases represent drug-resistant TB. There are strong regional variations. In Belarus in 2012, for instance, 32.2% of new cases and 75.6% of retreatment patients had MDR-TB, within an overall estimated TB incidence of 70 per 100,000 people.<sup>2</sup> By contrast, in South Africa in 2012, 1.8 % of new cases and 6.7% of retreatment patients had MDR- TB within an overall estimated TB incidence of 1,000 per 100,000 people.<sup>1</sup> The precise global trends of drug-resistant TB incidence and prevalence are currently ill-defined because of poor surveillance and detection methods. Worldwide in 2012, only 77,000 patients with MDR-TB started treatment, representing only 17% of the total estimated cases. Of the cohort of patients with MDR-TB who started treatment in 2010, only 48% had a successful treatment outcome, reflecting high rates of either loss to follow up and/or mortality.<sup>1</sup> In 2012, 78,000 MDR-TB cases were estimated to have occurred in the European region, as defined by the WHO, but only approximately 30,000 patients were detected and even fewer started treatment.<sup>3</sup> XDR-TB has now been detected in 92 countries and, on average, 9.6% of MDR-TB cases are also XDR-TB cases.<sup>17</sup> Recently, there have been publications on totally drug resistant TB (TDR-TB).<sup>20</sup> Such patients were resistant to all second-line anti-TB medication tested. However, TDR-TB is not officially recognised nomenclature and, therefore, should not currently be used as official terminology.<sup>21</sup>

The definitions of MDR-TB and XDR-TB relate intimately to the outcome of treatment. Using individual patient data from cohort studies, Falzon et al reported a successful treatment outcome for 64% of patients with MDR-TB, but only 40% of patients with XDR-TB.<sup>22</sup> These compare with old data suggesting a spontaneous TB cure rate of approximately 30%.<sup>23</sup> Such data highlight current challenges regarding drug-resistant TB care, with poor case detection and

treatment outcome. The increasing proportion of MDR-TB among new TB cases, as seen for instance in Belarus and China, demonstrates that MDR-TB strains are being actively transmitted from person to person with increasing frequency.<sup>19,24</sup> Paradoxically, based on old data for susceptible TB, it can be argued that, from a public health perspective, poor treatment programmes are worse than no TB control at all.<sup>25,26</sup>

Multidrug-resistant tuberculosis (MDR-TB) is an increasing global problem, with most cases arising from a mixture of physician error and patient non-compliance during treatment of susceptible TB. The extent and burden of MDR-TB varies significantly from country to country and region to region. It should be stressed that MDR-TB is a man-made phenomenon - poor treatment, poor drugs and poor adherence lead to the development of MDR-TB. Use of inadequate treatment in patients with drug-resistant TB strains will fail to cure a significant proportion of such cases and can create even more resistance to the drugs in use. Ongoing transmission of established drug-resistant strains in health care facilities is also believed to be a major source of new drug resistant cases.<sup>1</sup>

Globally in 2016, following WHO guidance issued in May 2016, all cases of rifampicin-resistant TB (RR-TB), including those with multidrug-resistant TB (MDR-TB), should be treated with a second-line MDR-TB treatment regimen. Globally in 2015, there were an estimated 480 000 new cases of MDR-TB and an additional 100 000 people with rifampicin-resistant TB who were also newly eligible for MDR-TB treatment; India, China and the Russian Federation accounted for 45% of these cases.<sup>2</sup> India is one of the high burden countries for tuberculosis as well as drug-resistant tuberculosis. As per WHO's "Global Tuberculosis Report, 2015", India account for an estimated 480,000 new cases of MDR-TB and an additional 100,000 people with rifampicin resistant TB (RR-TB). People with rifampicin resistant TB are now eligible for the same treatment as people with MDR TB.<sup>3</sup>

Multidrug-resistant tuberculosis (MDR-TB) is defined as resistance to at least isoniazid and rifampicin.<sup>4</sup> Treatment of MDR-TB is difficult, complicated, much costlier, challenging and needs experience and skills. Reserve drugs are frequently associated with very high rates of unacceptable adverse drug reactions, needing frequent interruption and change of regimen.

Therefore, it is imperative to monitor and treat adverse drug reactions developed by the patients. This approach ensures better compliance of patients and good treatment outcome. At the same time, data regarding ADRs of second-line anti-tubercular drugs in India are scanty. Hence, the

aim of this study was to assess the adverse drug reactions of anti-tubercular drugs used to treat MDR-TB in India.<sup>5</sup>

## **METHODS**

Present study was carried out at Damien Foundation Urban Leprosy & TB Centre, Nellore with prior approval of institutional Ethics Committee. It was a prospective, observational clinical study.

## **INCLUSION CRITERIA**

- Patient of either sex of age more than 20 years – 50 years with tuberculosis.
- Diagnosed cases of MDR- TB, enrolled under RNTCP(NTEP) program.
- Agreed to adhere tuberculosis treatment regime prescribed.
- Patient who provide written informed consent and ready to give follow up

## **EXCLUSION CRITERIA**

- History of Patients receiving ART Treatment
- Patients with deranged Liver and Kidney function tests.
- History of patient suffering from any other chronic disease condition requiring any concomitant medication.
- Patients those were transferred to XDR-TB/whose diagnosis were changed.
- Not ready to give informed consent.
- Not ready to give follow up.

## **PROCEDURE:**

Patients for this study were included from all patients diagnosed to have MDR-TB and XDR-TB (Isoniazid and Rifampicin resistance) and rifampicin resistance and admitted in Drug Resistance Tuberculosis Centre. Data was collected from June 2019 to March 2020. All study subjects were evaluated after written informed consent. Thorough detailed history was taken regarding the demographic profile, present complaints, past history of tuberculosis, history of any addiction, family history of Tuberculosis. Detailed general and systemic examination was done to find out any abnormalities. Body mass index (BMI) was calculated in all the patients. Pre-treatment investigations done included informed consent, urine for albumin, sugar and pregnancy test for

female patients (if 18 to 45 yrs. old), complete haemogram, renal and liver function test, Thyroid function test, psychiatric evaluation, Audiometry (SOS), Vision Acuity Test (SOS).

### **TYPES OF DRUG-RESISTANT TB (WHO 2013b) (TYPES ARE NOT MUTUALLY EXCLUSIVE)**

**Monoresistance:** Resistance to one first-line anti-TB drug only.

**Polydrug resistance:** Resistance to more than one first-line anti-TB drug, other than both isoniazid and rifampicin.

**Multidrug resistance (MDR):** Resistance to at least both isoniazid and rifampicin.

**Rifampicin resistance (RR):** Resistance to rifampicin detected using phenotypic or genotypic methods, with or without resistance to other anti-TB drugs. It includes any resistance to rifampicin, whether monoresistance, multidrug resistance, polydrug resistance, or extensive drug resistance.

**Extensive drug resistance (XDR):** Resistance to any fluoroquinolone, and at least one of three second-line injectable drugs (capreomycin, kanamycin, and amikacin), in addition to multidrug resistance.

### **TREATMENT REGIMEN:**

The standardized regimen consisted of an intensive phase (IP) of 6-9 months with 6 drugs, namely kanamycin (Km), ofloxacin (Ofx) (now levofloxacin), ethionamide (Eto), pyrazinamide (Z), ethambutol (E), and cycloserine (Cs) given daily. This was followed by a continuation phase (CP) of 18 months of 4 drugs, namely Ofx (now levofloxacin), Eto, E and Cs. At the end of 6 months of treatment, if the fourth month culture remained positive, the IP was extended for a further 3 months. Doses of the drugs were chosen according the weight range to which patient belonged.


All patients enrolled to the study were treated with a daily supervised regimen. All patients were monitored daily for adverse drug reactions after starting regimen till the patients remains admitted in hospital and later followed up personally or telephonically at regular intervals of 2 monthly bases and will be asked questions regarding possible adverse drug reactions of the drug which are prescribed to them. In between the 2 monthly follow up in OPD, telephonic questioning regarding adverse drug reactions will be asked on the any day of first week of every month. Anticipated ADRs will be identified and assessed. The causality of adverse drug

reactions will be assessed as per Naranjo's causality assessment scale, for severity of the adverse drug reactions as per Modified Hartwig-Siegel Scale. At the end of the study, these adverse event records will be analyzed and statistically interpreted.

## RESULTS

**Table 1: Demographic profile of patents.**

Parameters		Number	Percentage (%)
<b>Gender</b>	Male	104	69.33
	Female	46	30.66
<b>Age group (in years)</b>	<20	26	17.33
	21-30	40	26.66
	31-40	60	40.00
	41-50	24	16.00
<b>Weight (Kg)</b>	16-29	00	00
	26-45	48	32.00
	46-70	88	58.66
	>70	14	9.33




**Fig. NO: 1 Demographic profile of patents.**

A total number of n=150 patients who were on DOTS plus therapy were included in this study around 104 (69.33%) were male and 46 (30.66%) were female. Patients of different age group ranging from 18-50 years were reported in the study. 26 patients were under 20 years of age (17.33%), 21-30 of 40 patients (26.66%), followed by 60 resides in the age of 31-40 (40.00%), Rest were in 41- 50 years age group (16.00%) (Table 1).

**Table 2: Incidence of Adverse Drug reactions.**

Type of ADR	No. of patients	Percentage (%)
Gastrointestinal	24	27.27
Nausea, vomiting	16	18.18
Anorexia	02	2.27
Epigastric discomfort	05	5.68
Change of taste	02	2.27
Diarrhea	02	2.27
Hepatitis	01	1.13
Ototoxicity	07	7.95
Tinnitus +Vertigo	02	2.27

Psychiatric manifestations		
Insomina+Suicidal Tendencies	03	3.40
Depression	02	2.27
Altered behavior	01	1.13
Insomnia+ Suicidal Tendencies+Depression	01	1.13
Hallucination + Suicidal Tendency	01	1.13
Peripheral neuropathy	02	2.27
Vision defect Impaired visual acuity	02	2.27
Color discrimination	00	00
Skin	02	2.27
Pruritus with rash	02	2.27
Pruritus without rash	01	1.13
Injection site pain and swelling	04	4.54
Renal dysfunction Deranged RFT	02	2.27
Musculoskeletal Arthralgia	03	3.40
Total	88	100

**Fig. NO: 2 Bar diagram of Types of ADR**

Out of these 150 patients 88 patients developed ADRs of various types (Table 2). Among this ADRs, most were observed in males (63/71.59%) and remaining (25/28.40%) were females. The overall incidence of ADRs was 56.48%. ADRs in this study were categorized according to the systems affected like gastrointestinal system, ototoxicity, psychiatric manifestations and other systems like skin, vestibular, musculoskeletal etc. Majority of ADRs were related to gastrointestinal system (24 cases/27.27%) followed by ototoxicity (7cases/7.95%), Psychiatric Manifestations (03 Cases/3.40%), other systems (23 cases). Nausea and Vomiting was the most common ADR (21/34.43%) followed by Inj. site pain swelling (4/4.54%).


Out of the 150 drug resistance tuberculosis patients, patients were divided in the different weight bands according to it 48 (32.00%) patients in weight band 26- 45kg followed by 88 (58.66%) patients in weight band above 70kg followed by 14 (9.33%) patients in weight band 26- 45kg . Drug resistance pattern in out of 150 patients, 85 (56.66%) patients showing rifampicin mono-resistance while 65 (43.33%) patients showing Isoniazid and Rifampicin

Resistance.

The main action taken in patients with detected ADR was Withhold and Replacement of drug seen. The action mainly was taken when patients with psychiatric ADRs required withdrawal of cycloserine which was replaced with PAS. one patients required pyrazinamide withdrawal for peripheral neuropathy. While Kanamycin was replaced with PAS in patients suffers from ototoxicity .

**Table 3: Causality of ADRs induced by anti TB drugs according to Naranjo algorithm.**

Sr. no	Type	No. of patients	Percentage
1	Probable	37	42.04
2	Possible	51	57.95
3	Certain	00	00
Total		88	100



**Fig. NO:3 Causality of ADRs induced by anti TB drugs according to Naranjo algorithm.**

The causality assessment of ADRs revealed that 5 (21.31%) cases were detected as Definite, 51 (57.95%) as possible and 37 (42.04%) as probable reactions.

## DISCUSSION

The present observational study has evaluated a DOTS- Plus program, with special reference to Adverse Drug effects in which standard treatment of drug resistant tuberculosis cases as per RNTCP guidelines has been started in this DR-TB Centre. In the present study of 150 patients, the age group ranged from 18 to 50 years. Maximum number of cases was in the age group 31-40yrs (40.00%) followed by 21-30yrs (26.66%). The median age of the patients in present study was 31.78 years, as compared to the reports in which the median age was 28 years.<sup>6</sup> And in another study it was reported as 26 years respectively.

In the present study, majority of the patients were males 104 (69.33%) and Females 46 (30.66%). similar observations were noted by authors in a study (males 65.79% and females 34.21%).<sup>2</sup> and proportion of males to females was 54.54% and 45.46% respectively.<sup>6</sup>

Weight band: Of the 88 drug resistance tuberculosis patients in this study, majority of patients were in the weight band of 26 to 70 Kg (76.66%). Whereas, a study observed that majority patients were above 40 Kg (51.43%). Majority of the drug resistance tuberculosis patients were underweight before the start of treatment. In Present study, rifampicin mono resistance was found in 52.78%, while both isoniazid and rifampicin resistance were found in 47.22% patients. Initially, when our DR-TB center started only solid cultures were available in the program due to which both rifampicin and isoniazid resistance was reported together. As line probe assay became available, rifampicin mono resistance cases started getting picked up.

In this study ADRs were observed in 58.66% patient's, a finding comparable to present study reports notified in different studies.<sup>7-8</sup> The ADR reported in present study were, Gastrointestinal, Ototoxicity, Psychiatric manifestations, Injection site swelling/pain, Arthralgia, Skin, Renal Involvement, Vision defect, peripheral neuropathy.

Gastro intestinal symptoms were most common adverse reaction observed in this study that is 24(27.27%) similar to other studies.<sup>9-10</sup> on the contrary other studies have found observed gastrointestinal ADRs in 42%, 60% and 100% patients respectively.<sup>7,8,12,13</sup> Hepatotoxicity was noted in 1(1.64%) patient only. Similarly finding were reported other authors.<sup>11,13</sup> They were mild but required immediate treatment. These gastrointestinal symptoms occurred mostly within a week of starting treatment. No patient required alteration in DOTS-Plus treatment due to gastrointestinal ADRs. Ototoxicity 7 (7.95%) was second most common ADR observed in this

study of which decreased hearing 5 and tinnitus and vertigo in 2 patients. These findings were similar to observations in a study which reported ototoxicity as second most common ADR after gastrointestinal ADR and frequency of ototoxicity.<sup>2, 11, 14</sup> Whereas another study reported ototoxicity in 7.95% patients.<sup>14</sup> Kanamycin was withdrawn in 80% of these patients and substituted with PAS (p- amino salicylic acid).

Psychiatric 3 (3.40%) manifestations were the third most common adverse reaction in this study of which insomnia was the most common followed by suicidal tendency, depression and altered behavior in descending order. Psychiatric ADRs were less common in this study as compared to 15.9%.<sup>7</sup> and 15%.<sup>15</sup> in other studies. All patients with psychiatric manifestation required withdrawal of cycloserine which was replaced with PAS (P-amino salicylic acid).

Injection site swelling/pain 4 (4.54%) was fourth common ADR observed in this study. In contrast, it was reported in a study that injection site swelling/pain seen in 21.05% patients.<sup>8</sup> None of the patients required withdrawal of injection Kanamycin. Arthralgia 3 (3.40%) was fifth common ADR observed in this study. Similar observation was seen in 4.5% and 7.94% respectively.<sup>9,11</sup> In contrast, it was observed in the studies that arthralgia was seen in 31% and 23.68% patients.<sup>8,14</sup> Skin Adverse drug reactions ADR observed in this study was 5 (5.68%) of which pruritus without rash in 1 and pruritus with rash in 4 patient. Frequency of skin reaction found in this study is similar 4%, 1.58% and 4.5%.<sup>7,11,16</sup> On the one of the study reported cutaneous reactions in 43.3% patients.<sup>13</sup>

Renal involvement was seen 2(2.27%) patients in this study which is similar to observation noted in different other studies 1.58%, 2.7% and 2% respectively.<sup>9,11,12</sup> Renal involvements were seen in the form of borderline derangement of serum creatinine (2mg%) which improved in few weeks and none required withdrawal of injection kanamycin. Other ADR including Visual defect in 2 (2.27%), Peripheral Neuropathy 2(2.27). similar findings seen in a study with frequency of visual disturbance 1(0.9%) and peripheral neuropathy 3 (2.7%).<sup>9</sup>

In present study Causality assessment of 61 ADRs was done by Naranjo's Causality Scale, out of 88 ADRs, 37(42.04%) into possible category and 51(57.95%) fall into Probable category. None of categorized into 'Certain' category. The severity of ADRs in the present study was assessed by Modified Hartwig and sigel scale. The distribution of 88 ADRs as Mild 43.18%, moderate 54.54% and sever 2.27%, as the study population the patients was hospitalized for ADRs, higher number of ADRs belonged to "Moderate "grade.

## CONCLUSION

Drugs for treating MDR-TB strains involve a long-term exposure and have greater toxicity effects. A high frequency of adverse drug reactions is one of the major challenges in the treatment of MDR-TB. Pharmacovigilance now become important component of drug treatment, Drug therapy and active Pharmacovigilance goes hand in hand. The present study evaluated pattern and frequency of adverse drug reactions in patients receiving treatment for Multi-drug resistant tuberculosis and assessed their severity and causality. A majority of ADRs is possible in causality assessment and more of them are seems to be treatable and preventable.

## REFERENCES

1. Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India; New Delhi. Central TB Division. Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India. New Delhi: May 2012.
2. WHO. Global Tuberculosis Report 2016. [Internet]. 2016. Available at: <http://scholar.google.com/scholar?hl=en&btnG=Search&dq=intitle:No+Title#0>
3. National and state statistics TB statistics for India. Organisation WH, Control GT. MDRTB Statistics for India. 2015:1-9.
4. Joseph P, Desai VB, Mohan NS, Fredrick JS, Ramachandran R, Raman B, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. The Ind J of Med Resea. 2011 May;133(5):529.
5. Prasad R. Management of multi-drug resistant tuberculosis Practitioner's view point. Indian Journal of Tuberculosis. 2007;54:3-11.
6. Arora VK, Sarin R, Singla R, Khalid UK, Mathuria K, Singla N, et al. DOTS-Plus for patients with multidrug-resistant tuberculosis in India: early results after three years. Ind J of Che Disea and All Scienc. 2007;49(2):75.
7. Singla R, Sarin R, Khalid UK, Mathuria K, Singla N, Jaiswal A, et al. Seven-year DOTS-Plus pilot experience in India: Results, constraints and issues. The International Journal of Tuberculosis and Lung Disease. 2009;13:976-81.
8. Hire R, Kale AS, Dakhale GN, Gaikwad N. A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in Central India. Medit J of Hem and Infec Disea. 2014;6(1).
9. Singh BD, Ghulam H, Kadri SM, Qureshi W, Kamili MA, Singh H et al. Multidrug-

- Resistant and extensively drug resistant tuberculosis in Kashmir, India. *J Infect Dev Ctries.* 2010;4(1):19-23.
10. Kapadia VK, Tripathi SB. Analysis of 63 patients of MDR TB on DOTS plus regimen: An LG hospital, TB Unit, Ahmadabad experience. *Guj Med J.* 2013;68(2):52-7.
  11. Singh R, Gothi D, Joshi JM. Multidrug Resistant Tuberculosis: Role of Previous Treatment with Second Line Therapy on Treatment Outcome. *Lung India.* 2007;24:54-7.
  12. Furin JJ, Mitnick CD, Shin SS, Bayona J, Becerra MC, Singler JM, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. *Int J tuberc lung dis.* 2001;5(7):648-55.
  13. Jain K, Desai M, Dikshit RK. Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. *J Pharmacol Pharmacother.* 2014;5(2):145-9.
  14. Bloss E, Kukša L, Holtz TH, Riekstina V, Skripčonoka V, Kammerer S, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004. *Int J tuberc lung dis.* 2010 Mar 1;14(3):275-81.
  15. Törün T, Güngör G, Özmen I, Bölükbaşı Y, Maden E, Bıçakçı B, Atac G, Sevim T, Tahaoğlu K. Side effects associated with the treatment of multidrug-resistant tuberculosis. *Int J tuberc lung dis.* 2005 Dec 1;9(12):1373-7.
  16. Wai yew W, Kuen CC, Hung CC, Cheeuk MTC. Outcomes of patients with multidrug resistant pulmonary tuberculosis treated with Ofloxacin/Levofloxacin containing regimens. *Chest.* 2000;177:744-51.
  17. World Health Organization. Global Tuberculosis Report. Geneva: WHO, 2013.
  18. Skrahina A, Hurevich H, Zalutskaya A et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. *Bull WHO* 2013;91:36–45.
  19. World Health Organization. European Center of Disease Control: Tuberculosis surveillance and monitoring in Europe. Geneva: WHO, 2013.
  20. Udwardia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. *Clin Infect Dis* 2012;54:579–81.
  21. Udwardia ZF, Amale RA, Ajbani KK, Rodrigues CS. Nomenclature of drug-resistant tuberculosis. *Lancet Infect Dis* 2013;13:917.

22. Falzon D, Gandhi N, Migliori GB et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. *Eur Respir J* 2013;42:156–68.
23. National Tuberculosis Institute. Tuberculosis in a rural population of South India: a five-year epidemiological study. *Bull WHO* 1974;51:473–88.
24. Zhao Y, Xu S, Wang L et al. National survey of drug-resistant tuberculosis in China. *N Engl J Med* 2012;366:2161–70.
25. 9 Chiang CY, Van Deun A, Enarson DA. A poor drug-resistant tuberculosis programme is worse than no programme: time for a change. *Int J Tuberc Lung Dis* 2013;17:714–8.
26. 10 Grzybowski S, Enarson D. Results in pulmonary tuberculosis patients under various treatment program conditions. *Bull Int Union Tuberc* 1978;53:70–5.